Literature DB >> 22190018

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Ana Puda1, Jelena D Milosevic, Tiina Berg, Thorsten Klampfl, Ashot S Harutyunyan, Bettina Gisslinger, Elisa Rumi, Daniela Pietra, Luca Malcovati, Chiara Elena, Michael Doubek, Michael Steurer, Natasa Tosic, Sonja Pavlovic, Paola Guglielmelli, Lisa Pieri, Alessandro M Vannucchi, Heinz Gisslinger, Mario Cazzola, Robert Kralovics.   

Abstract

Chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) have an inherent tendency to progress to acute myeloid leukemia (AML). Using high-resolution SNP microarrays, we studied a total of 517 MPN and MDS patients in different disease stages, including 77 AML cases with previous history of MPN (N = 46) or MDS (N = 31). Frequent chromosomal deletions of variable sizes were detected, allowing the mapping of putative tumor suppressor genes involved in the leukemic transformation process. We detected frequent deletions on the short arm of chromosome 6 (del6p). The common deleted region on 6p mapped to a 1.1-Mb region and contained only the JARID2 gene--member of the polycomb repressive complex 2 (PRC2). When we compared the frequency of del6p between chronic and leukemic phase, we observed a strong association of del6p with leukemic transformation (P = 0.0033). Subsequently, analysis of deletion profiles of other PRC2 members revealed frequent losses of genes such as EZH2, AEBP2, and SUZ12; however, the deletions targeting these genes were large. We also identified two patients with homozygous losses of JARID2 and AEBP2. We observed frequent codeletion of AEBP2 and ETV6, and similarly, SUZ12 and NF1. Using next generation exome sequencing of 40 patients, we identified only one somatic mutation in the PRC2 complex member SUZ12. As the frequency of point mutations in PRC2 members was found to be low, deletions were the main type of lesions targeting PRC2 complex members. Our study suggests an essential role of the PRC2 complex in the leukemic transformation of chronic myeloid disorders.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190018     DOI: 10.1002/ajh.22257

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  51 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression.

Authors:  Chang-Liang Su; Tao-Ran Deng; Zhen Shang; Yi Xiao
Journal:  Int J Hematol       Date:  2015-05-05       Impact factor: 2.490

3.  Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation provides evidence for their common myelomonocytic origin.

Authors:  Andrea Bodmer; Thomas Menter; Darius Juskevicius; Christian Arranto; Friedel Wenzel; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2017-01-23       Impact factor: 4.064

Review 4.  Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Authors:  Friederike Pastore; Ross L Levine
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

Review 5.  Chromatin modifiers and the promise of epigenetic therapy in acute leukemia.

Authors:  S M Greenblatt; S D Nimer
Journal:  Leukemia       Date:  2014-03-10       Impact factor: 11.528

6.  MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.

Authors:  Minoru Terashima; Shoichiro Tange; Akihiko Ishimura; Takeshi Suzuki
Journal:  J Biol Chem       Date:  2016-11-16       Impact factor: 5.157

7.  JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

Authors:  Hamza Celik; Won Kyun Koh; Ashley C Kramer; Elizabeth L Ostrander; Cates Mallaney; Daniel A C Fisher; Jingyu Xiang; William C Wilson; Andrew Martens; Alok Kothari; Gregory Fishberger; Eric Tycksen; Darja Karpova; Eric J Duncavage; Youngsook Lee; Stephen T Oh; Grant A Challen
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

8.  miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.

Authors:  Ruggiero Norfo; Roberta Zini; Valentina Pennucci; Elisa Bianchi; Simona Salati; Paola Guglielmelli; Costanza Bogani; Tiziana Fanelli; Carmela Mannarelli; Vittorio Rosti; Daniela Pietra; Silvia Salmoiraghi; Andrea Bisognin; Samantha Ruberti; Sebastiano Rontauroli; Giorgia Sacchi; Zelia Prudente; Giovanni Barosi; Mario Cazzola; Alessandro Rambaldi; Stefania Bortoluzzi; Sergio Ferrari; Enrico Tagliafico; Alessandro M Vannucchi; Rossella Manfredini
Journal:  Blood       Date:  2014-08-05       Impact factor: 22.113

9.  Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner.

Authors:  Huafeng Xie; Jian Xu; Jessie H Hsu; Minh Nguyen; Yuko Fujiwara; Cong Peng; Stuart H Orkin
Journal:  Cell Stem Cell       Date:  2013-11-14       Impact factor: 24.633

Review 10.  Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.

Authors:  Itys Comet; Eva M Riising; Benjamin Leblanc; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.